I-Mab Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Raj Kannan
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | less than a year |
CEO ownership | n/a |
Management average tenure | less than a year |
Board average tenure | 4.8yrs |
Recent management updates
Recent updates
I-Mab: Trading Below Net Cash With Multiple Upside Options
Feb 18We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn Rate
Feb 08I-Mab: Another CD47 Inhibitor Biotech With Great Potential
Sep 27I-Mab gets Chinese nod to start phase 3 combo treatment trial for myelodysplastic syndrome
Sep 13I-Mab Biopharma Non-GAAP EPADS of -$1.54, revenue of $7.74M
Aug 30I-Mab and senior executives may buy $40M worth of shares; stock up 10%
Aug 23Newsflash: I-Mab (NASDAQ:IMAB) Analysts Have Been Trimming Their Revenue Forecasts
Aug 20I-Mab doses first patient in phase 1 trial of TJ-CD4B in solid tumors in China
Jul 22I-Mab Valuation Offers A Biotech Investment Opportunity
Jun 23Companies Like I-Mab (NASDAQ:IMAB) Are In A Position To Invest In Growth
May 24I-Mab Shaken By Management Moves, Merger Talk And Delisting Threat
May 06Bearish: Analysts Just Cut Their I-Mab (NASDAQ:IMAB) Revenue and EPS estimates
Apr 01I-Mab Founder Retakes Reins In Latest Shakeup Ahead Of Commercialization Phase
Jan 03I-Mab Gets Boost From Latest Industry Signals On New Cancer Treatment
Oct 14Drug Maker I-Mab Wins Plaudits As Analysts Urge Caution On Soaring Stock
Jul 02I-Mab adds gastrointestinal oncology expert Andrew Zhu to Scientific Advisory Board
Jun 21I-Mab in talks seeking a billion-dollar deal for cancer therapy: Bloomberg
Jun 14CEO
Raj Kannan (59 yo)
less than a year
Tenure
Mr. Raj Kannan serves as Chief Executive Officer and Director at I-Mab since June 22, 2023. He served as Chief Executive Officer and Director at Aerie Pharmaceuticals, Inc since December 20, 2021 until Nov...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | less than a year | no data | no data | |
Chief Financial Officer | less than a year | no data | no data | |
Vice President of Investor Relations | no data | no data | no data | |
Senior VP and Head of U.S. & EU Business Development | 4.2yrs | no data | no data | |
Head of US site | no data | no data | no data | |
Interim Chief Medical Officer | less than a year | no data | no data | |
Senior Director of Investor Relations | no data | no data | no data |
0.6yrs
Average Tenure
Experienced Management: IMAB's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | less than a year | no data | no data | |
Member of Scientific Advisory Board | 4.9yrs | no data | no data | |
Member of Scientific Advisory Board | 4.8yrs | no data | no data | |
Member of Scientific Advisory Board | 4.8yrs | no data | no data | |
Interim Chairperson | 4.3yrs | no data | no data | |
Independent Director | 4.3yrs | no data | no data | |
Independent Director | 4.3yrs | no data | no data | |
Director | 5.9yrs | no data | no data | |
Member of Scientific Advisory Board | 4.8yrs | no data | no data | |
Member of Scientific Advisory Board | 4.8yrs | no data | no data | |
Member of Scientific Advisory Board | 4.8yrs | no data | no data | |
Member of Scientific Advisory Board | 3.7yrs | no data | no data |
4.8yrs
Average Tenure
60yo
Average Age
Experienced Board: IMAB's board of directors are considered experienced (4.8 years average tenure).